相关实验视频
Updated: Jan 16, 2026

Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[扩散性大B细胞淋巴瘤:当前治疗策略和未来前景]
1Department of Hematology, National Cancer Center Hospital.
扩散性大B细胞淋巴瘤 (DLBCL) 治疗情况正在改善. 像CAR T细胞疗法这样的新型免疫疗法为复发或耐药性疾病患者提供了新的希望,改变了结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是日本最常见的淋巴瘤亚型.
- 目前最先进的化学免疫疗法治疗了大约50%的DLBCL患者.
- 标准治疗后复发或耐药的DLBCL预后不佳.
研究的目的:
- 审查当前DLBCL治疗策略.
- 为了突出DLBCL临床开发的最新进展.
- 专注于DLBCL的新兴免疫疗法.
主要方法:
- 对当前DLBCL治疗的文献综述.
- 对新疗法最新临床试验数据的分析.
- 专注于免疫治疗剂,包括CAR T细胞和双特异性抗体.
主要成果:
- 新型免疫疗法对复发性/耐药性DLBCL的治疗环境产生了重大影响.
- 化学抗原受体 (CAR) T细胞疗法和双特异性抗体显示出有希望的结果.
- 目前正在进行的试验正在探索将这些新型药物整合到前线DLBCL治疗中.
结论:
- 免疫疗法在治疗复发性或耐火性DLBCL方面取得了重大进展.
- 进一步的研究和临床试验对于优化新药的使用至关重要.
- 这些进展为难以治疗的DLBCL患者提供了改善的预后.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...